Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics Inc. has announced the proposed adoption of the 2025 A Share Incentive Scheme and the 2025 H Share Option Scheme, aimed at incentivizing its directors, senior management, and other key personnel. These schemes are designed to enhance the company’s operational efficiency and align the interests of its stakeholders, pending approval at an Extraordinary General Meeting (EGM). The company plans to issue restricted shares and share options to eligible participants, which include 87 individuals, representing about 7.87% of its workforce.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on the development and production of vaccines and other biologics, catering to both domestic and international markets.
Average Trading Volume: 2,319,877
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.63B
See more insights into 6185 stock on TipRanks’ Stock Analysis page.